Primary Motility  Disorders of the  Esophagus
 The Esophageal
 Esophagogastric  Junction

  Browse by Author
  Browse by Movies
Volume: Barrett's Esophagus
Chapter: Markers

What information on potential tumor progression in Barrett's metaplasia can be derived from the genetic models?
K.A. Skinner  

What does a prominent lymphocytic infiltrate in high-grade dysplasia mean in terms of tumor progression?
R.D. Odze  

Is there any relationship between histologic findings, proliferating cell nuclear antigen expression and ploidy analysis by flow cytometry or by image analysis?
R.D. Odze  

The development of apoptosis as a consequence of experimental duodenogastroesophageal reflux
V. Schumpelick, B. Dreuw, N. Ponschek, K. Ophoff, J. Nutzmann  

Is impaired apoptosis as detected by immunohistochemistry sequence a potential marker for the development of dysplasia and carcinoma?
U. Halm, K. Caca, A. Tannapfel, J. Mössner  

What is the role of alteration of bcl-2 proto-oncogene (blocking apoptosis) in the development of dysplasia and carcinoma?
G.Y. Lauwers  

Can decrease or loss of expression of intestinal markers (Villin) be correlated with development of dysplasia or adenocarcinoma?
R. Lascar, R.C. Fitzgerald, G. Triadafilopoulos  

What is the comparative rate of p53 overexpression in Barrett's patients with and without dysplasia?
H.S. Garewal  

Does staining for p53 improve the histologic diagnosis of any epithelial abnormality in Barrett's mucosa?
K. Geboes  

What is the value of immunohistochemistry in addition to molecular analysis to explain the discordance that can exist between gene mutation and protein expression?
H.S. Garewal  

Can the incidence of p53 mutations be overestimated on the basis of the level of expression of p53 protein?
S.C. Evans, A.G. Casson  

How can the contradictory findings of p53 gene mutation be explained? Can differences in technique be sufficient reason?
S.C. Evans, A.G. Casson  

What is the prevalence of p53 mutations in Barrett's mucosa and adenocarcinoma?
S.C. Evans, A.G. Casson  

How to treat a Barrett patient with a p53 mutation and no evidence of invasive carcinoma?
S. Ramel  

Is there p53 over-expression in Barrett's patients with or without dysplasia?
G. Tougas, C. Dienenfeld  

Is there any diagnostic or prognostic value for the quantitation of p53 or Ki-67 expression in Barrett's mucosa?
J.W. van Sandick, J.P.A. Baak, W. Polkowski, G.J.A. Offerhaus, H. Obertop, J.J.B. van Lanschot  

What can be expected from Ki-67 nuclear antigen expression in the follow-up of patients with dysplasia?
E. Montgomery  

What is the in vivo value of chromosomal 9p21 allelic loss and CDKN2 gene mutations in detecting neoplastic progression before aneuploidy and cancer?
D.G. Beer  

Have environmental factors been identified for each genetic step in the dysplasiacarcinoma sequence?
M. Conio, R. Filiberti, S. Blanchi  

Are there predictable changes in CD44 protein expression during the dysplasiacarcinoma sequence?
D.G. Beer  

What is the value of the mucosal content of prostaglandin E2, epidermal growth factor and transforming growth factor á in the surveillance of Barrett's patients?
C. Poplawski, M. Marcinkiewicz, T. Zbroch, Z. Namiot, J. Sarosiek  

What information exists as to biomarkers in short segment Barrett's esophagus?
H.S. Garewal  

What are the protective benefits versus risks of columnar epithelium in Barrett's esophagus?
R.C. Fitzgerald, R. Lascar, B.S. Kaur, G. Triadafilopoulos  

Publication date: August 2003 OESO©2015